Dx4Life secures funding ahead of launch of its groundbreaking rapid test for IVF treatments

Lund, Sweden – The SmiLe company Dx4Life has completed a new share issue, raising 6.4 million SEK to prepare for the launch of a unique rapid test that is set to significantly increase the success rate of IVF treatments.  

The majority of hormone treatments for in-vitro fertilization (IVF) fail. Too few eggs mature and can be retrieved, even though women undergo multiple treatments. The reason for this has long been unknown. However, Professor Yvonne Lundberg Giwercman, in her research at CRC, Lund University, has discovered the cause: genetic variations among women affect how effectively they respond to different types of hormones. 

To translate her discovery into practice, Yvonne Lundberg Giwercman has developed an advanced rapid test that identifies the hormone treatment best suited for each woman based on her genetic profile. The test is intended for use in IVF clinics, is easy to perform, and requires only a heater, i.e. a water bath. It provides quick results in the form of a color change. The test is based on an entirely new platform technology, developed by Lundberg Giwercman. 

Through her company Dx4Life, she is now working within the framework of SmiLe's incubator program to commercialize the test, which has the potential to revolutionize fertility care and drastically improve IVF success rates. 

The funding round was led by Gobia Enterprises. The proceeds from the share issue will be used to secure the company’s patent portfolio, achieve ISO certification for the company, CE mark the product, and validate the test at fertility clinics. The goal is to launch the product on the market within approximately one year. 

“We are starting within IVF care, where there is a significant unmet need, but my new platform technology can also be used to identify other genes and thereby be applied to additional diagnoses. Having access to SmiLe’s network is incredibly important to me, as I am new to the role of CEO—I am primarily a researcher. I look forward to being part of a community with other companies and receiving support from SmiLe to drive the business toward commercialization,” says Yvonne Lundberg Giwercman, CEO of Dx4Life. 

"This is a great example of how world-leading research, with the support we provide through SmiLe Venture Hub and funding opportunities, gets the chance to be commercialized and thereby contributes to significantly improved IVF care in the near future. This is something in high demand. It is very exciting to support Yvonne and, in doing so, also all future patients," says Ulrika Ringdahl, CEO of SmiLe Venture Hub. 

 
For more information, please contact: 
  
Ulrika Ringdahl, CEO of SmiLe Venture Hub,  
+46 (0)73 656 6232, ulrika.ringdahl@smileincubator.life 

Yvonne Lundberg Giwercman, CEO of Dx4Life,  

+46 (0)70 597 7904, Yvonne@dx-4life.com